66000-41-7 Usage
Commonly used in synthesis of pharmaceuticals and agrochemicals
The compound has potential biological activities that make it useful in the production of drugs and pesticides.
Anti-inflammatory and antifungal properties
The compound has been studied for its ability to reduce inflammation and inhibit the growth of fungi, making it a valuable tool in drug discovery and development.
Trifluoromethyl group attached to phenyl ring
The presence of this group enhances the compound's stability and lipophilicity, making it more suitable as a drug candidate.
Versatile and important chemical in medicinal chemistry
The compound's unique properties and potential applications make it a valuable asset in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 66000-41-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,0,0 and 0 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 66000-41:
(7*6)+(6*6)+(5*0)+(4*0)+(3*0)+(2*4)+(1*1)=87
87 % 10 = 7
So 66000-41-7 is a valid CAS Registry Number.
66000-41-7Relevant academic research and scientific papers
COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
-
Page/Page column 70, (2012/02/01)
Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically ac
PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS
-
Page/Page column 24-25, (2011/11/06)
Provided are pyrido[3,4-d]pyrimidinyl acetamide derivatives as Transient Receptor Potential Ankyrin (TRPA) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Transient Receptor Potential Ankyrin 1 (TRPAl). Also provided herein are processes for preparing the compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1. Formula (I).